Femasys FemBloc System Achieves MDSAP Certification
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy FEMY?
Femasys announced that its FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program, MDSAP. The MDSAP certification positions the Company to accelerate regulatory and commercial execution across key global markets, including the United States, Canada, Japan, Australia, and Brazil. In the U.S., FDA recognition of MDSAP reflects a high level of quality system maturity and supports regulatory readiness as the Company advances its trial toward PMA submission.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FEMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FEMY
Wall Street analysts forecast FEMY stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.570
Low
3.00
Averages
4.75
High
6.50
Current: 0.570
Low
3.00
Averages
4.75
High
6.50
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Femasys Grants Stock Options to New Employees
- Stock Option Grant: Femasys granted 185,000 stock options to two new employees in February 2026, with exercise prices set at $0.50 and $0.57, reflecting the company's commitment to incentivizing new talent.
- Vesting Schedule: The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting at 25% each year over the next three years, ensuring long-term employee retention and contribution.
- Market Positioning and Innovation: Femasys focuses on developing fertility and non-surgical permanent birth control products, with its FemaSeed and FemBloc offerings providing a unique competitive edge, particularly in European and international markets.
- Clinical Trials and Regulatory Progress: Femasys's FemBloc product received regulatory approvals in Europe, the UK, and New Zealand in 2025, and is currently undergoing the FINALE pivotal trial for FDA approval, indicating strong growth potential in the reproductive health sector.
See More
FemBloc Achieves MDSAP Certification, Accelerating Global Market Expansion
- MDSAP Certification Achievement: The FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP), significantly enhancing the company's regulatory and commercial execution capabilities across key markets such as the U.S., Canada, Japan, Australia, and Brazil, which is expected to accelerate global market entry.
- Manufacturing Credibility Boost: The MDSAP certification not only enhances FemBloc's manufacturing credibility but also supports ongoing commercialization in Europe, reducing regulatory risks and providing greater operational flexibility for market expansion in high-value regions.
- Non-Surgical Solution: FemBloc is the first non-surgical permanent birth control solution that safely creates natural scar tissue in the fallopian tubes using a patented delivery system, eliminating the risks and complexities associated with traditional surgical sterilization, which is expected to significantly lower healthcare costs and improve contraceptive options for women.
- Global Market Potential: The launch of FemBloc addresses the urgent global demand for permanent contraception while providing a safer, more convenient, and cost-effective option, enhancing the company's competitiveness in underpenetrated markets and is anticipated to attract strategic partnerships to drive future growth.
See More
Femasys Partners with OR Consulting for Swiss Market Launch
- Strategic Partnership: Femasys has announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland, including FemBloc permanent birth control and FemaSeed intratubal insemination, further advancing Femasys' European expansion strategy.
- Market Expansion Plan: This partnership signifies Femasys' continued market entry following successful launches in Spain and France, demonstrating the company's commitment to building a robust commercial platform across multiple countries.
- Product Innovation Advantage: FemBloc, the first non-surgical permanent birth control method, received full regulatory approval in Europe in 2025, and is expected to meet the growing demand in women's health with its effective and safe profile.
- Market Potential: Switzerland is recognized as a key market for women's health innovation, and the collaboration between Femasys and OR Consulting aims to enhance patient options through close cooperation with physicians, facilitating effective navigation in complex markets.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
Femasys (FEMY) Receives Nasdaq Approval for 180-Day Compliance Extension Until July 2026
- Compliance Extension: Femasys has received Nasdaq approval for a 180-day extension until July 13, 2026, to meet the minimum closing bid price requirement of $1.00 per share, ensuring the company's continued listing status on the capital market.
- Stable Listing Status: The extension notice does not immediately affect Femasys's listing status on Nasdaq, indicating the company's resilience and operational capability amid market challenges.
- Market Reaction: FEMY shares fell 0.81% in premarket trading to $0.5809, reflecting cautious investor sentiment regarding the company's compliance progress, which may impact future financing and market confidence.
- Financing Context: Recently, Femasys secured $12 million in financing and received FDA approval for the final FemBloc trial, demonstrating positive advancements in product development and fundraising despite compliance pressures.
See More
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
See More
Femasys Grants Stock Options to New Employees
- Stock Option Grant: Femasys granted 185,000 stock options to two new employees in February 2026, with exercise prices set at $0.50 and $0.57, reflecting the company's commitment to incentivizing new talent.
- Vesting Schedule: The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting at 25% each year over the next three years, ensuring long-term employee retention and contribution.
- Market Positioning and Innovation: Femasys focuses on developing fertility and non-surgical permanent birth control products, with its FemaSeed and FemBloc offerings providing a unique competitive edge, particularly in European and international markets.
- Clinical Trials and Regulatory Progress: Femasys's FemBloc product received regulatory approvals in Europe, the UK, and New Zealand in 2025, and is currently undergoing the FINALE pivotal trial for FDA approval, indicating strong growth potential in the reproductive health sector.
See More
FemBloc Achieves MDSAP Certification, Accelerating Global Market Expansion
- MDSAP Certification Achievement: The FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP), significantly enhancing the company's regulatory and commercial execution capabilities across key markets such as the U.S., Canada, Japan, Australia, and Brazil, which is expected to accelerate global market entry.
- Manufacturing Credibility Boost: The MDSAP certification not only enhances FemBloc's manufacturing credibility but also supports ongoing commercialization in Europe, reducing regulatory risks and providing greater operational flexibility for market expansion in high-value regions.
- Non-Surgical Solution: FemBloc is the first non-surgical permanent birth control solution that safely creates natural scar tissue in the fallopian tubes using a patented delivery system, eliminating the risks and complexities associated with traditional surgical sterilization, which is expected to significantly lower healthcare costs and improve contraceptive options for women.
- Global Market Potential: The launch of FemBloc addresses the urgent global demand for permanent contraception while providing a safer, more convenient, and cost-effective option, enhancing the company's competitiveness in underpenetrated markets and is anticipated to attract strategic partnerships to drive future growth.
See More
Femasys Partners with OR Consulting for Swiss Market Launch
- Strategic Partnership: Femasys has announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland, including FemBloc permanent birth control and FemaSeed intratubal insemination, further advancing Femasys' European expansion strategy.
- Market Expansion Plan: This partnership signifies Femasys' continued market entry following successful launches in Spain and France, demonstrating the company's commitment to building a robust commercial platform across multiple countries.
- Product Innovation Advantage: FemBloc, the first non-surgical permanent birth control method, received full regulatory approval in Europe in 2025, and is expected to meet the growing demand in women's health with its effective and safe profile.
- Market Potential: Switzerland is recognized as a key market for women's health innovation, and the collaboration between Femasys and OR Consulting aims to enhance patient options through close cooperation with physicians, facilitating effective navigation in complex markets.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
Femasys (FEMY) Receives Nasdaq Approval for 180-Day Compliance Extension Until July 2026
- Compliance Extension: Femasys has received Nasdaq approval for a 180-day extension until July 13, 2026, to meet the minimum closing bid price requirement of $1.00 per share, ensuring the company's continued listing status on the capital market.
- Stable Listing Status: The extension notice does not immediately affect Femasys's listing status on Nasdaq, indicating the company's resilience and operational capability amid market challenges.
- Market Reaction: FEMY shares fell 0.81% in premarket trading to $0.5809, reflecting cautious investor sentiment regarding the company's compliance progress, which may impact future financing and market confidence.
- Financing Context: Recently, Femasys secured $12 million in financing and received FDA approval for the final FemBloc trial, demonstrating positive advancements in product development and fundraising despite compliance pressures.
See More
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
See More
